Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Jonathan Cook made Professor of Clinical Trials and Medical Statistics


Jonathan Cook was successful in the 2023 University Recognition of Distinction exercise

OCTRU Pashion Study In the News


The ongoing PASHION study being ran by the Surgical Intervention Trials Unit group was in the BBC news last week.

Antibiotic bone cement found not to reduce infection after hip replacement


A large trial has found that using high-dose dual-antibiotic loaded cement is unlikely to reduce the risk of surgical site infection in people who have had a hip replacement.

Kadoorie research paper receives EFORT gold award


A paper for the PATH-2 trial has received a gold award from the European Federation of National Associations of Orthopaedics and Traumatology (EFORT).

Jonathan Cook elected as Society for Clinical Trials board member


Associate Professor Jonathan Cook has been elected to the Society for Clinical Trials (SCT) board.

New approach to nail bed injury surgery could significantly cut NHS costs


According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.

OCTRU - delivering answers to important clinical questions


The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease


Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis


Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Load More